M Eric Kohler
Overview
Explore the profile of M Eric Kohler including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1210
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pham-Danis C, Novak A, Danis E, McClellan S, Leach L, Yarnell M, et al.
Cancer Cell
. 2025 Mar;
43(3):482-502.e9.
PMID: 40068599
Chimeric antigen receptor (CAR) T cells induce responses in patients with relapsed/refractory leukemia; however, long-term efficacy is frequently limited by relapse. The inability to target antigen-low cells is an intrinsic...
2.
DeGolier K, Danis E, DAntonio M, Cimons J, Yarnell M, Kedl R, et al.
Nat Immunol
. 2025 Jan;
26(1):68-81.
PMID: 39747430
Although chimeric antigen receptor (CAR) T cells are effective against B-lineage malignancies, post-CAR relapse is common, and efficacy in other tumors is limited. These challenges may be addressed through rational...
3.
Wu M, Valenca-Pereira F, Cendali F, Giddings E, Pham-Danis C, Yarnell M, et al.
Nat Commun
. 2024 May;
15(1):4444.
PMID: 38789421
Mitochondrial respiration is essential for the survival and function of T cells used in adoptive cellular therapies. However, strategies that specifically enhance mitochondrial respiration to promote T cell function remain...
4.
Hay Z, Kim D, Cimons J, Knapp J, Kohler M, Quansah M, et al.
J Immunol
. 2024 Feb;
212(8):1381-1391.
PMID: 38416029
Granzymes are a family of proteases used by CD8 T cells to mediate cytotoxicity and other less-defined activities. The substrate and mechanism of action of many granzymes are unknown, although...
5.
DeGolier K, Danis E, DAntonio M, Cimons J, Yarnell M, Kedl R, et al.
Res Sq
. 2024 Jan;
PMID: 38196657
Chimeric antigen receptor T cells are an effective therapy for B-lineage malignancies. However, many patients relapse and this therapeutic has yet to show strong efficacy in other hematologic or solid...
6.
7.
Murphy L, Marians R, Miller K, Brenton M, Mallo R, Kohler M, et al.
Cytotherapy
. 2022 Oct;
25(1):94-102.
PMID: 36253252
Background Aims: Vector copy number (VCN), an average quantification of transgene copies unique to a chimeric antigen receptor (CAR) T-cell product, is a characteristic that must be reported prior to...
8.
Logan G, Miller K, Kohler M, Loi M, Maddux A
Pediatr Crit Care Med
. 2022 Oct;
23(12):e595-e600.
PMID: 36194016
Objectives: Cytokine release syndrome (CRS) is a potentially lethal toxicity associated with chimeric antigen receptor T cell therapy for pediatric acute lymphoblastic leukemia (ALL). Outcomes after critical illness due to...
9.
Niswander L, Graff Z, Chien C, Chukinas J, Meadows C, Leach L, et al.
Haematologica
. 2022 Aug;
108(2):457-471.
PMID: 35950535
Chimeric antigen receptor (CAR) T-cell immunotherapies targeting CD19 or CD22 induce remissions in the majority of patients with relapsed/refractory B-cell acute lymphoblastic leukemia (ALL), although relapse due to target antigen...
10.
Liao W, Kohler M, Fry T, Ernst P
Exp Hematol
. 2021 Sep;
103:73-74.
PMID: 34555335
No abstract available.